Qlife Holding - Chinese partnership deal offers great potential

Meet and ask questions to CEO Thomas Warthoe from Qlife on 11 December 2023 at 11 AM.

Monday 4 December Qlife Holding announced that its Letter of Intent (LOI) with Hipro Biotechnology, turned into a collaboration agreement. Hipro Biotechnology will sell, distribute, and produce the point-of-care Egoo Health system developed by Olife Holding on the Chinese market, primarily to hospitals of which there are more than 35.000 in China. Hipro Biotechnologies have exposure to 14.000 of those hospitals today.

You’re welcome to send in your questions before the event.

Read more about the agreement here:https://www.inderes.dk/analyst-comments/qlife-holding-chinese-partnership-deal-offers-great-potential

Disclaimer: HC Andersen Capital receives payment from Qlife for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 06/12-2023 10:38 AM.